{"id":"W3164028683","doi":"10.1136/annrheumdis-2021-eular.1002","title":"POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"LEO Pharma; Foundation for Research in Rheumatology; Genentech; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Placebo; Psoriasis; Psoriatic arthritis; Internal medicine; Psoriasis Area and Severity Index; Adverse effect; Gastroenterology; Arthritis; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000899587,0.0009157442,0.002545672,0.0002867453,0.0002960105,0.001099085,0.0004942679,0.001309303,0.004386389],"category_scores_gemma":[0.0008056571,0.0004005528,0.001571158,0.0002657591,0.000592741,0.001034347,0.0001974145,0.002520198,0.001408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000514464,"about_ca_system_score_gemma":0.0005078875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004807195,"about_ca_topic_score_gemma":0.0009161121,"domain_scores_codex":[0.9995193,0.0002232775,0.00003353517,0.00008634309,0.00005211429,0.00008546845],"domain_scores_gemma":[0.9995586,0.0001222238,0.00009638031,0.00003139676,0.00002891613,0.0001623357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8824747,0.006786223,0.002356615,0.0006260669,0.001456521,0.0001233159,0.00005486049,0.001342427,0.02684847,0.0001893146,0.002197792,0.07554366],"study_design_scores_gemma":[0.5190588,0.4307406,0.03083916,0.0000910391,0.001840158,0.000684167,0.0001148761,0.002614593,0.008533476,0.0004274409,0.004947813,0.0001078803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883173,0.006711826,0.0002173689,0.0004055951,0.0002530316,0.0001846124,0.001044924,0.000124288,0.002740959],"genre_scores_gemma":[0.9944825,0.001503058,0.0001949064,0.0004185119,0.0001615875,0.0001156189,0.001379254,0.00002503355,0.001719545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004386389,"threshold_uncertainty_score":0.01467395,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03588851344233161,"score_gpt":0.2916870868243451,"score_spread":0.2557985733820134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}